Ruthenium-106 versus iodine-125 plaque brachytherapy of 571 choroidal melanomas with a thickness of ≥5.5 mm

Ruthenium-106 versus iodine-125 plaque brachytherapy of 571 choroidal melanomas with a thickness of ≥5.5 mm

BackgroundEpiscleral brachytherapy is the most common eye-preserving treatment for medium-sized choroidal melanomas. γ-emitting iodine-125 (125I) and β-emitting ruthenium-106 (106Ru) are widely used. The latter is however generally reserved for thinner tumours (

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:British journal of ophthalmology 2020-01, Vol.104 (1), p.26-32
Hauptverfasser: Filì, Maria, Trocme, Eric, Bergman, Louise, See, Thonnie Rose Ong, André, Helder, Bartuma, Katarina, Girnita, Leonard, All-Eriksson, Charlotta, Seregard, Stefan, Stålhammar, Gustav
Format: Artikel
Sprache:eng
Schlagworte:
Iodine
Life Sciences & Biomedicine
Medical prognosis
Medicin och hälsovetenskap
Melanoma
Metastasis
Mortality
Ophthalmology
Patients
Radiation therapy
Radioisotopes
Science & Technology
Skin cancer
Tumors
Ultrasonic imaging
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:BackgroundEpiscleral brachytherapy is the most common eye-preserving treatment for medium-sized choroidal melanomas. γ-emitting iodine-125 (125I) and β-emitting ruthenium-106 (106Ru) are widely used. The latter is however generally reserved for thinner tumours (
ISSN:0007-1161
1468-2079
1468-2079
DOI:10.1136/bjophthalmol-2018-313419